Skip to main content
Top
Published in: Clinical Drug Investigation 3/2011

01-03-2011 | Original Research Article

Importance of C-Reactive Protein Level in Predicting Non-Response to Additional Intravenous Immunoglobulin Treatment in Children with Kawasaki Disease

A Retrospective Study

Authors: Dr Satoru Iwashima, Mituaki Kimura, Takamichi Ishikawa, Takehiko Ohzeki

Published in: Clinical Drug Investigation | Issue 3/2011

Login to get access

Abstract

Background: Intravenous immunoglobulin (IVIG) therapy in the acute stage of Kawasaki disease (KD; mucocutaneous lymph node syndrome) is the treatment of first choice for preventing the development of coronary artery lesions (CALs). Failure of initial treatment with IVIG remains the most consistent risk factor for CALs. However, there are few reports on non-responders to additional IVIG therapy in KD.
Objective: The goal of the present study was to predict non-responders to additional IVIG therapy in children with KD.
Methods: This was a retrospective study aimed at predicting non-responders to additional IVIG therapy for KD in a cohort of 446 patients. The IVIG response group (‘responders’) was defined as those patients who were afebrile 48 hours after administration of initial IVIG. The IVIG non-response group (‘non-responders’) was defined as those patients who remained febrile 48 hours after administration of initial IVIG and was divided into two subgroups: (i) those patients who remained febrile 48 hours after administration of additional IVIG (non-responders 1), and (ii) those patients who were afebrile 48 hours after additional IVIG (non-responders 2).
Results: Ninety-one patients received additional IVIG; of these, 25 patients (non-responders 1) received additional rescue therapy because no improvement was observed and 66 patients (non-responders 2) were afebrile. Mean ± SD C-reactive protein (CRP) levels were higher in non-responders 1 than in non-responders 2 (12.05 ± 5.14 vs 7.67 ± 4.99 mg/dL; p = 0.002). The optimal cutoff point of sensitivity and specificity for predicted non-responders was ≥8 mg/dL. The sensitivity and specificity for prediction of IVIG response was 76.0% and 63.6%, respectively. Forty-three patients had a CRP level of ≥8 mg/dL after initial IVIG, 18 of whom developed CALs (eight persistent lesions and ten transient lesions). Forty-eight patients had a CRP level of <8mg/dL after initial IVIG, of whom only eight developed CALs (all transient).
Conclusion: We have discovered a biomarker able to identify KD patients at high risk of complications who require additional IVIG treatment, thus avoiding overtreatment of low-risk individuals. We suggest that patients who have a CRP level of ≥8 mg/dL after initial IVIG are likely to fail additional IVIG and may require further IVIG plus rescue therapy.
Literature
1.
go back to reference Morens DM, Anderson LH, Hurwitz ES. National surveillance of Kawasaki disease. Pediatrics 1980; 65: 21–5PubMed Morens DM, Anderson LH, Hurwitz ES. National surveillance of Kawasaki disease. Pediatrics 1980; 65: 21–5PubMed
2.
go back to reference Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986; 108: 923–7PubMedCrossRef Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986; 108: 923–7PubMedCrossRef
3.
go back to reference Furusho K, Sato K, Soeda T, et al. High-dose intravenous gamma-globulin for Kawasaki disease. Lancet 1984; 2: 1055–8PubMedCrossRef Furusho K, Sato K, Soeda T, et al. High-dose intravenous gamma-globulin for Kawasaki disease. Lancet 1984; 2: 1055–8PubMedCrossRef
4.
go back to reference Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633–9PubMedCrossRef Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633–9PubMedCrossRef
5.
go back to reference Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998 Dec; 17(12): 1144–8PubMedCrossRef Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998 Dec; 17(12): 1144–8PubMedCrossRef
6.
go back to reference Hashino K, Ishii M, Iemura M, et al. Retreatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001 Jun; 43(3): 211–7PubMedCrossRef Hashino K, Ishii M, Iemura M, et al. Retreatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001 Jun; 43(3): 211–7PubMedCrossRef
7.
go back to reference Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-response to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000; 137: 172–6PubMedCrossRef Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-response to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000; 137: 172–6PubMedCrossRef
8.
go back to reference Durongpisitkul K, Soongswang J, Laohaprasitiporn D, et al. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003; 24: 145–8PubMedCrossRef Durongpisitkul K, Soongswang J, Laohaprasitiporn D, et al. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003; 24: 145–8PubMedCrossRef
9.
go back to reference Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007; 166: 131–7PubMedCrossRef Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007; 166: 131–7PubMedCrossRef
10.
go back to reference Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immune globulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149: 237–40PubMedCrossRef Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immune globulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149: 237–40PubMedCrossRef
11.
go back to reference Muta H, Ishii M, Furui J, et al. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 2006; 95: 189–93PubMedCrossRef Muta H, Ishii M, Furui J, et al. Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease. Acta Paediatr 2006; 95: 189–93PubMedCrossRef
12.
go back to reference Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immune globulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113: 2606–12PubMedCrossRef Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immune globulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113: 2606–12PubMedCrossRef
13.
go back to reference Ayusawa M, Sonobe T, Uemura S, et al., Kawasaki Disease Research Committee. Revision of diagnostic guidelines for Kawasaki disease (5th rev. ed.). Pediatr Int 2005; 47: 232–4PubMedCrossRef Ayusawa M, Sonobe T, Uemura S, et al., Kawasaki Disease Research Committee. Revision of diagnostic guidelines for Kawasaki disease (5th rev. ed.). Pediatr Int 2005; 47: 232–4PubMedCrossRef
14.
go back to reference Iwashima S, Seguchi M, Matubayashi T, et al. Ulinastatin therapy in Kawasaki disease. Clin Drug Investig 2007; 27: 91–6CrossRef Iwashima S, Seguchi M, Matubayashi T, et al. Ulinastatin therapy in Kawasaki disease. Clin Drug Investig 2007; 27: 91–6CrossRef
15.
go back to reference Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004; 163: 263–4PubMedCrossRef Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004; 163: 263–4PubMedCrossRef
16.
go back to reference Hayashibara H, Tanimoto K, Nagata I, et al. Normal levels of IgG subclass in childhood determined by a sensitive ELISA. Acta Paediatr Jpn 1993; 35: 113–7PubMedCrossRef Hayashibara H, Tanimoto K, Nagata I, et al. Normal levels of IgG subclass in childhood determined by a sensitive ELISA. Acta Paediatr Jpn 1993; 35: 113–7PubMedCrossRef
17.
go back to reference Arjunan K, Daniels SR, Meyer RA. Coronary artery caliber in normal children and patients with Kawasaki disease but without aneurysms: an echocardiographic and angiographic study. J Am Coll Cardiol 1986; 8: 1119–24PubMedCrossRef Arjunan K, Daniels SR, Meyer RA. Coronary artery caliber in normal children and patients with Kawasaki disease but without aneurysms: an echocardiographic and angiographic study. J Am Coll Cardiol 1986; 8: 1119–24PubMedCrossRef
18.
go back to reference Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341–7PubMedCrossRef Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341–7PubMedCrossRef
19.
go back to reference Sawaji Y, Haneda N, Yamaguchi S, et al. Coronary risk factors in acute Kawasaki disease: correlation of serum immunoglobulin levels with coronary complications. Acta Paediatr Jpn 1998; 40: 218–25PubMedCrossRef Sawaji Y, Haneda N, Yamaguchi S, et al. Coronary risk factors in acute Kawasaki disease: correlation of serum immunoglobulin levels with coronary complications. Acta Paediatr Jpn 1998; 40: 218–25PubMedCrossRef
20.
go back to reference Nakano H, Ueda K, Saito A, et al. Scoring method for identifying patients with Kawasaki disease at high risk of coronary artery aneurysms. Am J Cardiol 1986; 58: 739–42PubMedCrossRef Nakano H, Ueda K, Saito A, et al. Scoring method for identifying patients with Kawasaki disease at high risk of coronary artery aneurysms. Am J Cardiol 1986; 58: 739–42PubMedCrossRef
21.
go back to reference Iwasa M, Sugiyama K, Ando T, et al. Selection of high-risk children for immunoglobulin therapy in Kawasaki disease. Prog Clin Biol Res 1987; 250: 543–4PubMed Iwasa M, Sugiyama K, Ando T, et al. Selection of high-risk children for immunoglobulin therapy in Kawasaki disease. Prog Clin Biol Res 1987; 250: 543–4PubMed
22.
go back to reference Beiser AS, Takahashi M, Baker AL, et al. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 1998; 81: 1116–20PubMedCrossRef Beiser AS, Takahashi M, Baker AL, et al. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 1998; 81: 1116–20PubMedCrossRef
23.
go back to reference Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996 Jan; 128(1): 146–9PubMedCrossRef Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996 Jan; 128(1): 146–9PubMedCrossRef
24.
go back to reference Venugopalan P, Jaya S, Al-Azri MA, et al. Kawasaki disease resistant to immunoglobulin G therapy. Ann Trop Paediatr 2003 Sep; 23(3): 187–91PubMedCrossRef Venugopalan P, Jaya S, Al-Azri MA, et al. Kawasaki disease resistant to immunoglobulin G therapy. Ann Trop Paediatr 2003 Sep; 23(3): 187–91PubMedCrossRef
Metadata
Title
Importance of C-Reactive Protein Level in Predicting Non-Response to Additional Intravenous Immunoglobulin Treatment in Children with Kawasaki Disease
A Retrospective Study
Authors
Dr Satoru Iwashima
Mituaki Kimura
Takamichi Ishikawa
Takehiko Ohzeki
Publication date
01-03-2011
Publisher
Springer International Publishing
Published in
Clinical Drug Investigation / Issue 3/2011
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI
https://doi.org/10.2165/11538910-000000000-00000

Other articles of this Issue 3/2011

Clinical Drug Investigation 3/2011 Go to the issue